Trial Profile
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess the Immunogenicity and Safety of Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine in Adults and Elderly Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs NBP 607 QIV (Primary) ; NBP 607
- Indications Influenza virus infections
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors SK Chemicals
- 14 May 2015 New trial record
- 15 Mar 2015 SK Chemicals is in the final stage of this phase III clinical trial for a quadrivalent seasonal influenza vaccine, according to a media release.